DAWN · Day One Biopharmaceuticals, Inc.
$21.53
+0.00 (+0.00%)
At close · Apr 24
Market Cap
$2.22B
Shares
103.33M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$21.53
Open$21.53
Day$21.53–21.53
52W$5.64–21.53
Avg vol 30d2.2M
Short int6.6M · 6.4% float · 5.4d
Short vol34%
Last earningsFeb 24, 2026
DataMay 2021–Apr 2026
Filing10-K · Feb 24
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Feb 24, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Moderate
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+99%
above
Price vs 50-day avg
+17%
above
RSI (14)
81
overbought
MACD trend
Negative
52-week position
100%
near high
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+206%
trailing
YTD return
+131%
this year
Relative strength
+201%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $18 › 200d $11 — 50d above 200d
Institutional flow
Distributing
25 of 211 funds reported for Jun 30 · net -839.2K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.37% of float · ▼ -9.1% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
211 holders — near 3-yr high, broad support
Fundamentals
Revenue growth
+21%
Y/Y
EPS growth
−2%
Y/Y
Free cash flow
$-104.1M
Balance sheet
$197.1M
net cash
Quant / Vol
risk profile
Volatility
100%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
0.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2025
Ojemda net product revenue
· for 2026
Initiated
$225M – $250M
prior FY $158.18M
midpoint +50.1% Y/Y
Guided vs delivered
· last 1 settled
Full year revenue
full year 2025
guided $145M – $150M
$158.18M
Beat +7.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+99%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
81
Bearish
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $18 › 200d $11 — 50d above 200d
Institutional flow
Distributing
25 of 211 funds reported for Jun 30 · net -839.2K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.37% of float · ▼ -9.1% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
211 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $22 · 100%
52-wk high $22
vs 200-day avg +99%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Fourth quarter prescription volumes | 1,394 | Q4 2025 | — |
| Total 2025 prescriptions | 4,635 | Full year 2025 | — |
| Cash, cash equivalents, and short-term investments | $441.1M | As of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DAWN
this stock
Day One Biopharmaceuticals, Inc.
|
$2.22B | +131.0% | +20.6% | — | 6.4% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DAWN | +0.3% | +0.6% | +205.8% | +0.4% | +131.0% |
| SPY | -0.1% | +10.0% | +4.4% | +9.1% | +4.1% |
| vs SPY | +0.3% | -9.4% | +201.4% | -8.7% | +126.9% |